AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24849084
Drug: Pasireotide (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (900 μg subcutaneously twice daily for 7 days)
Trial: 21246843
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with oral administration of Felodipine (group A)
Trial: 21246843
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Felodipine only (group B)
Trial: 18794650
Drug: Add-on of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on of aripiprazole on a current regimen, wait for 4 weeks, and tapering of prior antipsychotics
Trial: 18794650
Drug: Add-on of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on of aripiprazole and simultaneous tapering of prior antipsychotics
Trial: 10073816
Drug: Vascular surgery
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular surgery with perioperative intensive care treatment
Trial: 2254672
Drug: Doxium 500
RxNorm normalized name: Dexium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxium 500 (1.5 g, 3 capsules/day)
Trial: 7016973
Drug: Dicyclomine hydrochloride
RxNorm normalized name: Dicyclomine Hydrochloride
DrugBank: Dicyclomine (DB00804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicyclomine hydrochloride 40 mg 4 times daily
Trial: 22956531
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Marsh model
Trial: 22956531
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Schnider model
Trial: 18797455
Drug: CAP (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP (capecitabine single agent)
Trial: 11819181
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 500 mg po bid
Trial: 10574107
Drug: Methylprednisolone 30
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 30 mg/kg (100 ml) given by slow intravenous infusion 90-60 minutes before operation
Trial: 1649422
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (40 patients)
Trial: 1649422
Drug: Immunomodulating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulating therapy with Sintomodulin (20 patients)
Trial: 25497747
Drug: Esmolol (500mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (500mcg/kg bolus followed by 100mcg/kg/min infusion)
Trial: 18517090
Drug: Enhanced Treatment
RxNorm normalized name: Thera-M Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment (ET)
Trial: 18517090
Drug: Minimal Treatment
RxNorm normalized name: Minimally modified low density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Treatment (MT)
Trial: 12757209
Drug: Proguanil 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proguanil 100 mg BID plus sulfamethoxazole 1,000 mg BID for 7 days
Trial: 7894098
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate (CP) applied twice daily for 16 days (phase 1)
Trial: 1657248
Drug: Heparin or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin or low molecular weight heparin (LMWH; Fragmin)
Trial: 6406438
Drug: Bupropion (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (450 to 750 mg/day)
Trial: 6406438
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 to 225 mg/day)
Trial: 26370148
Drug: Usual follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual follow-up treatment
Trial: 21992993
Drug: 0.1% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% timolol maleate gel
Trial: 21992993
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate gel
Trial: 17530933
Drug: HMB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB (3 g.d(‐1))
Trial: 17530933
Drug: HMBCr (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMBCr (12 g.d(‐1) with 3 g HMB, 3 g Cr, 6 g carbohydrates)
Trial: 15061303
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine 0.5 per cent
Trial: 9062158
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy and total parenteral nutrition (TPN)
Trial: 9062158
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy alone
Trial: 9062158
Drug: Chemotherapy (unspecified)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (unspecified)
Trial: 8458110
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose duteplase (0.16-0.29 MIU/kg)
Trial: 8458110
Drug: Middle dose
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle dose duteplase (0.30-0.41 MIU/kg)
Trial: 8458110
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose duteplase (0.43-0.74 MIU/kg)
Trial: 8458110
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of duteplase
Trial: 30321689
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + 9 weekly cycles of docetaxel + 3 years of androgen deprivation therapy (arm B)
Trial: 30321689
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + 3 years of luteinizing hormone-releasing hormone analogues (arm A)
Trial: 27450646
Drug: Sesamin capsules;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesamin capsules; 200 mg/day
Trial: 27450646
Drug: Placebo capsules;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules; 200 mg/day starch
Trial: 19410978
Drug: Egg group
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg group (640 mg/d additional dietary cholesterol)
Trial: 19410978
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (0 mg/d additional dietary cholesterol)
Trial: 16675507
Drug: Sparkling wine
RxNorm normalized name: Wine grape
DrugBank: Wine grape (DB10634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparkling wine (30 g of ethanol/day for 28 days)
Trial: 16675507
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (20 g of ethanol/day for 28 days)
Trial: 16675507
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (20 g of ethanol/day for 28 days)
Trial: 16675507
Drug: Gin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gin (30 g of ethanol/day for 28 days)
Trial: 15138203
Drug: ALA-PDT (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-PDT (single dose of 100 J/cm² at four hours) - PDT100 (n=13)
Trial: 15138203
Drug: ALA-PDT (fractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-PDT (fractionated dose of 20 and 100 J/cm² at one and four hours) - PDT20+100 (n=13)
Trial: 9757191
Drug: Post-operative chemotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative chemotherapy and pre-operative induction chemotherapy in patients with stage IIIA N2 disease
Trial: 9757191
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with thoracic radiotherapy (TRT) in unresectable, locally advanced NSCLC
Trial: 9757191
Drug: Timely combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely combination of TRT and chemotherapy
Trial: 9757191
Drug: Chemotherapeutic agents
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic agents as radiosensitizers
Trial: 9757191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TRT and new agents in unresectable, locally advanced NSCLC
Trial: 9757191
Drug: Cancer chemotherapy
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer chemotherapy for advanced NSCLC
Trial: 9757191
Drug: Cancer chemotherapy
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer chemotherapy in metastatic NSCLC
Trial: 9757191
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents (irinotecan, paclitaxel, docetaxel, vinorelbine, gemcitabine) along with combination chemotherapy
Trial: 8058236
Drug: Terodiline, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terodiline, 25 mg twice daily
Trial: 31583943
Drug: G‐CSF support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF support during EC and docetaxel
Trial: 31583943
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy without G‐CSF support
Trial: 31583943
Drug: G‐CSF use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF use
Trial: 19623435
Drug: Trazodone (5HT2a/c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (5HT2a/c antagonist)
Trial: 15213587
Drug: Evidence-based pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based pharmacotherapy algorithm
Trial: 11360134
Drug: Selenium and
RxNorm normalized name: Selenium and/or selenium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium and zinc supplementation (Se 200 microg/day and Zn 21 mg/day) for 50 days
Trial: 9340698
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30 mg daily)
Trial: 8369892
Drug: Hydrotherapy (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrotherapy (twice weekly for 6 weeks in addition to home exercises)
Trial: 3789649
Drug: Hydrochlorothiazide (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (20-50 mg/day)
Trial: 3789649
Drug: Indacrinone (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacrinone (50-100 mg/day)
Trial: 3789649
Drug: Indacrinone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacrinone plus amiloride (50-100 mg and 5-10 mg/day)
Trial: 30103772
Drug: C21 (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 (an angiotensin type 2 receptor agonist)
Trial: 30103772
Drug: Candesartan (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (an angiotensin receptor blocker)
Trial: 30103772
Drug: Saline/C21 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline/C21 monotherapy
Trial: 26259675
Drug: Uncoated mini-tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncoated mini-tablets
Trial: 21147783
Drug: Rocuronium (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.3 mg kg⁻¹)
Trial: 21147783
Drug: Alfentanil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (20 µg kg⁻¹)
Trial: 21147783
Drug: Placebo (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (i.v. saline 0.5 ml kg⁻¹)
Trial: 15018018
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg/g cream
Trial: 8219654
Drug: Insulin treatment;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin treatment; hemoglobin A1c before: 11.3 +/- 2.8, after: 7.0 +/- 1.0
Trial: 8219654
Drug: Sulfonylurea treatment;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea treatment; hemoglobin A1c before: 11.3 +/- 1.4, after: 7.3 +/- 0.9
Trial: 31729108
Drug: Magnolol additive
RxNorm normalized name: magnolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnolol additive (MA) at 100, 200, and 300 mg/kg for 3 weeks
Trial: 31729108
Drug: Colistin sulphate
RxNorm normalized name: Colistin sulphate
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin sulphate (CS) at 30 mg/kg for 3 weeks
Trial: 23908141
Drug: MCPH1-2550-CC genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCPH1-2550-CC genotype with 10-27 pack-years of smoking
Trial: 21918956
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (two cycles of cisplatin and 5-fluorouracil)
Trial: 21918956
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (two cycles of cisplatin and 5-fluorouracil)
Trial: 10507591
Drug: Intravenous antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antihistamines (diphenhydramine, 1 mg/kg, and cimetidine, 4 mg/kg)
Trial: 4028748
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of dipyridamole for 24 hours
Trial: 4028748
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 100 mg of aspirin daily
Trial: 28176386
Drug: Intensive bisphosphonate
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive bisphosphonate therapy (zoledronic acid)
Trial: 23538648
Drug: Food preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food preparation dependence
Trial: 21147262
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g/day for ≥1 month)
Trial: 12601676
Drug: Single-dose administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administration of Hypericum extract LI 160 (6 or 12 coated tablets, 5400 or 10800 microgram hypericin)
Trial: 12601676
Drug: Steady-state administration
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady-state administration of Hypericum extract LI 160 (initial dose of 6 tablets, 5400 microgram hypericin, followed by 3 x 1 tablets, 2700 microgram hypericin per day for 7 days)
Trial: 9122747
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) followed by autologous bone marrow transplantation
Trial: 26313157
Drug: MNTX-ER (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNTX-ER (500 mg)
Trial: 26313157
Drug: MNTX-SC (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNTX-SC (12 mg)
Trial: 26313157
Drug: MNTX-IR (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNTX-IR (500 mg)
Trial: 24980265
Drug: Live saxophone
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live saxophone music therapy (30 minutes)
Trial: 7749445
Drug: Continuous lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lateral rotation therapy
Trial: 17999977
Drug: Atazanavir (49
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir (49 on 400 mg once daily, and 53 on 300 mg plus 100 mg of ritonavir once daily)
Trial: 10716102
Drug: Methadone in
RxNorm normalized name: methadone Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone in decreasing doses (10 days)
Trial: 9213861
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg/12 hourly)
Trial: 9213861
Drug: Misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (200 micrograms/12 hourly)
Trial: 2996747
Drug: Intensive chemo‐radio‐immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemo‐radio‐immunotherapy regimen with cyclophosphamide, doxorubicin, vincristine, VP‐16, and cisplatin, followed by prophylactic whole‐brain radiotherapy and multifield radiotherapy.
Trial: 31605550
Drug: M. bovoculi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. bovoculi vaccine (2 doses)
Trial: 25719429
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride (1500 mg/d) plus chondroitin sulfate (1200 mg/d) for 28 days
Trial: 25195813
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT, DAT plus cilostazol)
Trial: 21345843
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAT) in carriers of CYP2C19 LOF allele
Trial: 21345843
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT) in carriers of CYP2C19 LOF allele
Trial: 21345843
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAT) in non-carriers of CYP2C19 LOF allele
Trial: 16484290
Drug: Iloprost treatment
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost treatment (intravenous infusion at progressively increasing doses from 0.5 to 2 ng/kg/min for 6 hours each day for 10 days, repeated every 3 months for 18 months)
Trial: 16484290
Drug: Iloprost treatment
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost treatment (new protocol)
Trial: 16484290
Drug: Iloprost treatment
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost treatment (different dosing schemes)
Trial: 12930167
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.3 g.kg body mass per day for 6 days)
Trial: 8884833
Drug: Hanks balanced
RxNorm normalized name: haNK
DrugBank: CD-16 NK-92 cells (DB17465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hanks balanced salt solution
Trial: 21678668
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline solution
Trial: 1326734
Drug: High-dose 4'-epi-doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 4'-epi-doxorubicin + cyclophosphamide (800 mg/m2)
Trial: 1326734
Drug: High-dose 4'-epi-doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 4'-epi-doxorubicin + cisplatin (60 mg/m2)
Trial: 3915883
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg once daily for 15 days
Trial: 3915883
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg once daily for 15 days
Trial: 31820603
Drug: Qinghou Liyan
RxNorm normalized name: Lian Fang
DrugBank: Nelumbo nucifera flower (DB14333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinghou Liyan granules, 5 g each time, 3 times a day, 7 days as one course, 4 courses total
Trial: 26945407
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion of recombinant human atrial natriuretic peptide (rhANP)
Trial: 22197455
Drug: Citrus-based juice
RxNorm normalized name: citrus juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus-based juice (300 mL daily for 6 months)
Trial: 22197455
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage (300 mL daily for 6 months)
Trial: 20711715
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump treatment with continuous glucose monitoring
Trial: 15199625
Drug: Jieyu pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jieyu pill (JYP)
Trial: 9814931
Drug: Low-energy density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy density shock wave therapy (1500 impulses of 0.06 mJ/mm2)
Trial: 9814931
Drug: High-energy density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy density shock wave therapy (1500 impulses of 0.28 mJ/mm2)
Trial: 28729302
Drug: Vosaroxin 70
RxNorm normalized name: vosaroxin
DrugBank: Vosaroxin (DB11999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosaroxin 70 mg/m2 on days 1 and 4 with decitabine 20 mg/m2 on days 1-5 every 4-6 weeks for up to seven cycles